Highlights•Novel therapeutic options are crucially needed for relatively rare but deadly
NETs.•Somatostatin analogs control tumor growth and symptoms in selected …

Low-intermediate grade neuroendocrine tumors (NETs) are usually slow-growing cancers
with a clinical course spanning few to several years managed with active surveillance …

Neuroendocrine tumours (NETs) constitute a heterogeneous group of neoplasms
characterised by variable endocrine activity and somatostatin receptor expression, with the …

Current treatment options for neuroendocrine tumors (NET) include somatostatin analogs,
interferon-α, peptide receptor-targeted therapy and cytotoxic chemotherapy. Most patients …

Neuroendocrine tumors (NETs) encompass a heterogeneous group of tumors
demonstrating varied clinical behavior. The field has recently witnessed several important …

Neuroendocrine tumors (NET) are a rare and heterogeneous group of neoplasms of a
relatively indolent nature whose incidence and prevalence are increasing. Despite the …

Simple Summary Neuroendocrine neoplasms are highly heterogeneous tumors in terms of
primary origin, molecular landscape, clinical presentation and behavior. To date, several …

Neuroendocrine tumors (NET) encompass a heterogeneous group of tumors demonstrating
varied clinical behavior. The field has recently witnessed several important developments …

Opinion statement Neuroendocrine neoplasms (NENs) constitute a heterogenous group of
malignancies. Translational research into NEN cell biology is the cornerstone for drug …

Neuroendocrine tumors (NETs) show low but increasing incidence and originate in multiple
organs, including the pancreas, midgut, caecum, rectum, appendix, colon, and lungs. Due to …